Barclays Starts Protagonist Therapeutics (PTGX) at Overweight

September 6, 2016 6:57 AM EDT
Get Alerts PTGX Hot Sheet
Price: $26.24 +5.51%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade PTGX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Barclays initiated coverage on Protagonist Therapeutics (NASDAQ: PTGX) with an Overweight rating and a price target of $18.00.

For an analyst ratings summary and ratings history on Protagonist Therapeutics click here. For more ratings news on Protagonist Therapeutics click here.

Shares of Protagonist Therapeutics closed at $12.08 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Barclays

Add Your Comment